| MeSH term | MeSH ID | Detail |
|---|---|---|
| Leukemia | D007938 | 74 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Liver Cirrhosis | D008103 | 67 associated lipids |
| Hematoma | D006406 | 5 associated lipids |
| Demyelinating Diseases | D003711 | 15 associated lipids |
| Peripheral Nervous System Diseases | D010523 | 33 associated lipids |
| Lymphoproliferative Disorders | D008232 | 7 associated lipids |
| Crohn Disease | D003424 | 12 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Metalidis C et al. | Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. | 2011 | Transplantation | pmid:21544031 |
| Shihab FS et al. | Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. | 2008 | Transplantation | pmid:18475181 |
| Ekberg H | Calcineurin inhibitor sparing in renal transplantation. | 2008 | Transplantation | pmid:18813097 |
| Fischer L et al. | Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. | 2015 | Transplantation | pmid:26151607 |
| Takaya S et al. | The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. | 1992 | Transplantation | pmid:1371195 |
| Francavilla A et al. | Inhibition of liver, kidney, and intestine regeneration by rapamycin. | 1992 | Transplantation | pmid:1371198 |
| Nakamura Y et al. | Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. | 2003 | Transplantation | pmid:12717187 |
| Calmus Y et al. | Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. | 2010 | Transplantation | pmid:20495510 |
| Ouyang J et al. | Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. | 2005 | Transplantation | pmid:15912108 |
| Egli A et al. | Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. | 2009 | Transplantation | pmid:19935369 |
| Abbott KC et al. | New-onset gout after kidney transplantation: incidence, risk factors and implications. | 2005 | Transplantation | pmid:16340779 |
| Villanueva G and Baldwin D | Rosiglitazone therapy of posttransplant diabetes mellitus. | 2005 | Transplantation | pmid:16340782 |
| Koneru B et al. | Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? | 1997 | Transplantation | pmid:9197350 |
| Sugitani A et al. | En bloc pancreas and kidney transplantation in a patient with limited vascular access. | 1997 | Transplantation | pmid:9197366 |
| Shihab FS et al. | Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. | 2009 | Transplantation | pmid:19202436 |
| Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
| Jindal RM et al. | Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7519799 |
| Bellon H et al. | The Effect of Immunosuppression on Airway Integrity. | 2017 | Transplantation | pmid:28471870 |
| Lufft V et al. | Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. | 1996 | Transplantation | pmid:8779695 |
| Barten MJ et al. | Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. | 2004 | Transplantation | pmid:15114077 |
| Gruessner RW et al. | Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. | 1997 | Transplantation | pmid:9415558 |
| Couzi L et al. | Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. | 2008 | Transplantation | pmid:18946343 |
| Horner BM et al. | Recipient damage after musculocutaneous transplant rejection. | 2008 | Transplantation | pmid:18946349 |
| Kaufman DB et al. | The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. | 1995 | Transplantation | pmid:7541579 |
| Herzog D et al. | Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. | 2006 | Transplantation | pmid:16534467 |
| Tanaka A et al. | Living related liver transplantation across ABO blood groups. | 1994 | Transplantation | pmid:7522363 |
| McDiarmid SV et al. | Factors affecting growth after pediatric liver transplantation. | 1999 | Transplantation | pmid:10030286 |
| Eckhoff DE et al. | The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. | 2000 | Transplantation | pmid:10830224 |
| Hanto DW and Chudzinski R | What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? | 2009 | Transplantation | pmid:19155968 |
| Ericzon BG et al. | Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. | 1997 | Transplantation | pmid:9000664 |
| Opelz G and Döhler B | Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. | 2008 | Transplantation | pmid:18698238 |
| Steinmüller TM et al. | The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. | 1994 | Transplantation | pmid:7524203 |
| Singh N et al. | Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. | 1994 | Transplantation | pmid:7524204 |
| Roberti I et al. | Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. | 1992 | Transplantation | pmid:1384182 |
| Langrehr JM et al. | Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. | 1992 | Transplantation | pmid:1384185 |
| Pape E et al. | Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. | 2015 | Transplantation | pmid:26308424 |
| Gruessner RW et al. | Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. | 1998 | Transplantation | pmid:9701258 |
| Pascual J et al. | Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. | 2010 | Transplantation | pmid:20335831 |
| Sahara H et al. | Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. | 2010 | Transplantation | pmid:21076382 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Min SI et al. | CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. | 2010 | Transplantation | pmid:21076384 |
| Chan L et al. | Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. | 2008 | Transplantation | pmid:18360262 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Saad ER et al. | Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. | 2008 | Transplantation | pmid:18360267 |
| Murase N et al. | Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. | 1993 | Transplantation | pmid:7678353 |
| Herold KC et al. | Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. | 1993 | Transplantation | pmid:7678356 |
| Gruber SA and Doshi MD | Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. | 2010 | Transplantation | pmid:20440195 |
| Burger CI et al. | Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. | 2010 | Transplantation | pmid:20440199 |
| Wong W et al. | 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? | 2005 | Transplantation | pmid:16082321 |
| Krämer BK et al. | Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. | 2012 | Transplantation | pmid:22858806 |